Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01558843
Other study ID # 201203034
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 1, 2012
Est. completion date October 1, 2016

Study information

Verified date April 2019
Source Washington University School of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This multicenter, observational, study will enroll severe neurologically injured patients both prospectively and retrospectively. The aims are to identify the percent of neurocritical care patients with sodium levels ≤ 135 mEq/L, describe treatment strategies employed, determine the correlation of clinical factors (i.e. GCS, ICP) with serum sodium concentrations in patients prior to sodium altering therapy, and evaluate outcomes through evaluation of length of stay, discharge disposition, and modified Rankin score (mRS).


Recruitment information / eligibility

Status Completed
Enrollment 400
Est. completion date October 1, 2016
Est. primary completion date October 1, 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- age = 18 years of age

- admitted to an intensive care unit for more than 48 hours

- ICD-9 codes for aneurysmal SAH, TBI, IPH, or intracranial tumor.

Exclusion Criteria:

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States The Johns Hopkins hospital Baltimore Maryland
United States University of Virginial Health System Charlottesville Virginia
United States University of Chicago Chicago Illinois
United States UC Health -University Hospital Cincinnati Ohio
United States Detroit Receiving Hospital Detroit Michigan
United States Spectrum Health Grand Rapids Michigan
United States Hartford Hospital Hartford Connecticut
United States University of Tennessee Knoxville Tennessee
United States UK Healthcare Lexington Kentucky
United States Jackson Memorial Hospital Miami Florida
United States Yale-New Haven Hospital New Haven Connecticut
United States Columbia University New York New York
United States Virginial Commonwealth University Richmond Virginia
United States St Louis University Hospital Saint Louis Missouri
United States Washington University Saint Louis Missouri
United States Memorial University Medical Center Savannah Georgia
United States Via Christi Hospital Wichita Kansas

Sponsors (2)

Lead Sponsor Collaborator
Washington University School of Medicine Astellas Pharma Inc

Country where clinical trial is conducted

United States,